This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the series here.
The inflammatory tumor microenvironment (TME) represents a critical area of investigation in hematological malignancies due to the complex interactions between malignant cells and the immune system. This special issue focuses on the mechanisms exploited by the innate and adaptive immune systems to promote cancer cell survival, growth, and resistance to therapy. The topics include the role of cytokines, chemokines, immune checkpoints, and immune cells in creating a pro-tumorigenic niche, as well as the impact of chronic inflammation on disease progression. By exploring the tumor-TME dynamics, the journal aims to advance the understanding of blood cancer initiation and progression as well as foster the development of novel anti-inflammatory / anti-immune therapeutic strategies, ultimately improving patients’ outcomes.
In the past few years, numerous preclinical and clinical studies have shed light on the multifaced role of the TME in fostering the development of leukemia, lymphoma, and multiple myeloma. It is now widely accepted that a deep understanding of the multifaced role of the TME will provide the basis for improved treatments for hematological malignancies This Research Topic will focus on the current knowledge of the mechanisms that the innate and adaptive immune systems co-opt to sustain the development of a pro-tumorigenic niche ultimately supporting tumor-cell survival, growth, and resistance to therapy. The contribution of several studies characterizing the different aspects of the TME in hematological malignancies could help to define effective therapeutic options.
We are interested in Original Research, Clinical Trials, Systematic Reviews, Reviews/Mini-Reviews, and Perspectives articles focusing on but not limited to the following areas:
- Role of the TME in leukemia, lymphoma and multiple myeloma;
- Studies on innate and adaptive immune responses relevant to immunotherapy;
- Studies defining the role of cytokines, chemokines, immune checkpoints, receptor-ligand interactions, and adhesion molecules in the TME that contribute to creating a pro-tumorigenic niche;
- Use of cellular therapies and T-cell engagers in leukemia, lymphoma and multiple myeloma;
- Novel combinations with immune checkpoint inhibitors;
- Novel combinations with monoclonal antibodies and bispecific antibodies;
- Cytokine-based immunotherapy;
- Vaccine-based immunotherapy.
Topic Editor Andrea Visentin is on the advisory board organized by Johnson&Johnson, Abbvie, BeiGene, AstraZeneca, and Takeda. They have also received financial support from Johnson&Johnson, BeiGene, AstraZeneca, and Taleda. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords:
Tumor microenvironment, hematologic malignancies, inflammation, immune checkpoint, chemokines/cytokines, therapeutic targeting
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the series
here.
The inflammatory tumor microenvironment (TME) represents a critical area of investigation in hematological malignancies due to the complex interactions between malignant cells and the immune system. This special issue focuses on the mechanisms exploited by the innate and adaptive immune systems to promote cancer cell survival, growth, and resistance to therapy. The topics include the role of cytokines, chemokines, immune checkpoints, and immune cells in creating a pro-tumorigenic niche, as well as the impact of chronic inflammation on disease progression. By exploring the tumor-TME dynamics, the journal aims to advance the understanding of blood cancer initiation and progression as well as foster the development of novel anti-inflammatory / anti-immune therapeutic strategies, ultimately improving patients’ outcomes.
In the past few years, numerous preclinical and clinical studies have shed light on the multifaced role of the TME in fostering the development of leukemia, lymphoma, and multiple myeloma. It is now widely accepted that a deep understanding of the multifaced role of the TME will provide the basis for improved treatments for hematological malignancies This Research Topic will focus on the current knowledge of the mechanisms that the innate and adaptive immune systems co-opt to sustain the development of a pro-tumorigenic niche ultimately supporting tumor-cell survival, growth, and resistance to therapy. The contribution of several studies characterizing the different aspects of the TME in hematological malignancies could help to define effective therapeutic options.
We are interested in Original Research, Clinical Trials, Systematic Reviews, Reviews/Mini-Reviews, and Perspectives articles focusing on but not limited to the following areas:
- Role of the TME in leukemia, lymphoma and multiple myeloma;
- Studies on innate and adaptive immune responses relevant to immunotherapy;
- Studies defining the role of cytokines, chemokines, immune checkpoints, receptor-ligand interactions, and adhesion molecules in the TME that contribute to creating a pro-tumorigenic niche;
- Use of cellular therapies and T-cell engagers in leukemia, lymphoma and multiple myeloma;
- Novel combinations with immune checkpoint inhibitors;
- Novel combinations with monoclonal antibodies and bispecific antibodies;
- Cytokine-based immunotherapy;
- Vaccine-based immunotherapy.
Topic Editor Andrea Visentin is on the advisory board organized by Johnson&Johnson, Abbvie, BeiGene, AstraZeneca, and Takeda. They have also received financial support from Johnson&Johnson, BeiGene, AstraZeneca, and Taleda. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords:
Tumor microenvironment, hematologic malignancies, inflammation, immune checkpoint, chemokines/cytokines, therapeutic targeting
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.